Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated ...
Pfizer (NYSE:PFE) has reportedly agreed to pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer risks associated with its now-discontinued heartburn ...
London: Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. PFE has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a Delaware ...
Along with GSK and Pfizer, Sanofi and Boehringer Ingelheim GmbH have been sued by consumers. After the federal cases were ...
Pfizer has agreed to pay between $200m to $250m to settle more than 10,000 US lawsuits over cancer risks associated with Zantac, Financial Times reports, citing two unidentified people briefed on the ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...
GSK’s shares fell sharply following a judge's decision to allow more than 70,000 lawsuits to proceed, alleging it’s Zantac ...
Is Eli Lilly stock a buy after a panel of advisors to the FDA unanimously backed its Alzheimer's drug? Is LLY stock a buy right now? Geron's (GERN) shares rise on approval of its first drug.
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...